{"pmid":32389615,"title":"The potential impact of COVID-19 on psychosis: A rapid review of contemporary epidemic and pandemic research.","text":["The potential impact of COVID-19 on psychosis: A rapid review of contemporary epidemic and pandemic research.","The COVID-19 outbreak may profoundly impact population mental health because of exposure to substantial psychosocial stress. An increase in incident cases of psychosis may be predicted. Clinical advice on the management of psychosis during the outbreak needs to be based on the best available evidence. We undertook a rapid review of the impact of epidemic and pandemics on psychosis. Fourteen papers met inclusion criteria. Included studies reported incident cases of psychosis in people infected with a virus of a range of 0.9% to 4%. Psychosis diagnosis was associated with viral exposure, treatments used to manage the infection, and psychosocial stress. Clinical management of these patients, where adherence with infection control procedures is paramount, was challenging. Increased vigilance for psychosis symptoms in patients with COVID-19 is warranted. How to support adherence to physical distancing requirements and engagement with services in patients with existing psychosis requires careful consideration. Registration details: https://osf.io/29pm4.","Schizophr Res","Brown, Ellie","Gray, Richard","Lo Monaco, Samantha","O'Donoghue, Brian","Nelson, Barnaby","Thompson, Andrew","Francey, Shona","McGorry, Pat","32389615"],"abstract":["The COVID-19 outbreak may profoundly impact population mental health because of exposure to substantial psychosocial stress. An increase in incident cases of psychosis may be predicted. Clinical advice on the management of psychosis during the outbreak needs to be based on the best available evidence. We undertook a rapid review of the impact of epidemic and pandemics on psychosis. Fourteen papers met inclusion criteria. Included studies reported incident cases of psychosis in people infected with a virus of a range of 0.9% to 4%. Psychosis diagnosis was associated with viral exposure, treatments used to manage the infection, and psychosocial stress. Clinical management of these patients, where adherence with infection control procedures is paramount, was challenging. Increased vigilance for psychosis symptoms in patients with COVID-19 is warranted. How to support adherence to physical distancing requirements and engagement with services in patients with existing psychosis requires careful consideration. Registration details: https://osf.io/29pm4."],"journal":"Schizophr Res","authors":["Brown, Ellie","Gray, Richard","Lo Monaco, Samantha","O'Donoghue, Brian","Nelson, Barnaby","Thompson, Andrew","Francey, Shona","McGorry, Pat"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389615","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.schres.2020.05.005","keywords":["covid-19","epidemic","mers","pandemic","psychosis","sars","schizophrenia"],"weight":0,"_version_":1666528580141580288,"score":9.490897,"similar":[{"pmid":32389516,"title":"Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series.","text":["Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series.","INTRODUCTION: The world is currently undergoing an extremely stressful scenario due to the COVID-19 pandemic. This unexpected and dramatic situation could increase the incidence of mental health problems, among them, psychotic disorders. The aim of this paper was to describe a case series of brief reactive psychosis due to the psychological distress from the current coronavirus pandemic. MATERIALS AND METHODS: We report on a case series including all the patients with reactive psychoses in the context of the COVID-19 crisis who were admitted to the Virgen del Rocio and Virgen Macarena University Hospitals (Seville, Spain) during the first two weeks of compulsory nationwide quarantine. RESULTS: In that short period, four patients met the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a brief reactive psychotic disorder. All of the episodes were directly triggered by stress derived from the COVID-19 pandemic and half of the patients presented severe suicidal behavior at admission. CONCLUSIONS: We may now be witnessing an increasing number of brief reactive psychotic disorders as a result of the COVID-19 pandemic. This type of psychosis has a high risk of suicidal behavior and, although short-lived, has a high rate of psychotic recurrence and low diagnostic stability over time. Therefore, we advocate close monitoring in both the acute phase and long-term follow-up of these patients.","Rev Psiquiatr Salud Ment","Valdes-Florido, Maria Jose","Lopez-Diaz, Alvaro","Palermo-Zeballos, Fernanda Jazmin","Martinez-Molina, Ivan","Martin-Gil, Victoria Eugenia","Crespo-Facorro, Benedicto","Ruiz-Veguilla, Miguel","32389516"],"abstract":["INTRODUCTION: The world is currently undergoing an extremely stressful scenario due to the COVID-19 pandemic. This unexpected and dramatic situation could increase the incidence of mental health problems, among them, psychotic disorders. The aim of this paper was to describe a case series of brief reactive psychosis due to the psychological distress from the current coronavirus pandemic. MATERIALS AND METHODS: We report on a case series including all the patients with reactive psychoses in the context of the COVID-19 crisis who were admitted to the Virgen del Rocio and Virgen Macarena University Hospitals (Seville, Spain) during the first two weeks of compulsory nationwide quarantine. RESULTS: In that short period, four patients met the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a brief reactive psychotic disorder. All of the episodes were directly triggered by stress derived from the COVID-19 pandemic and half of the patients presented severe suicidal behavior at admission. CONCLUSIONS: We may now be witnessing an increasing number of brief reactive psychotic disorders as a result of the COVID-19 pandemic. This type of psychosis has a high risk of suicidal behavior and, although short-lived, has a high rate of psychotic recurrence and low diagnostic stability over time. Therefore, we advocate close monitoring in both the acute phase and long-term follow-up of these patients."],"journal":"Rev Psiquiatr Salud Ment","authors":["Valdes-Florido, Maria Jose","Lopez-Diaz, Alvaro","Palermo-Zeballos, Fernanda Jazmin","Martinez-Molina, Ivan","Martin-Gil, Victoria Eugenia","Crespo-Facorro, Benedicto","Ruiz-Veguilla, Miguel"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389516","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.rpsm.2020.04.009","keywords":["covid-19","coronavirus","psychotic disorders","sars-cov-2","suicide","suicidio","trastornos psicoticos"],"locations":["Seville","Spain"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"weight":0,"_version_":1666528580164648960,"score":416.61954},{"pmid":32434611,"title":"The need for Early Intervention for Psychosis to persist throughout the covid-19 pandemic and beyond.","text":["The need for Early Intervention for Psychosis to persist throughout the covid-19 pandemic and beyond.","In the last three decades, Early Intervention for psychosis services have been established worldwide and have resulted in superior symptomatic and functional outcomes for people affected by psychotic disorders. These improved outcomes are a result of reducing delays to treatment and the provision of specialized, holistic interventions. The covid-19 pandemic poses significant challenges to the delivery of these services, such as undetected cases or long delays to treatment. Furthermore, the covid-19 pandemic will likely increase the mental health needs of communities, including the incidence of psychotic disorders. In this perspective piece, we provide suggestions as to how early intervention for psychosis services can adapt within this environment, such as utilizing novel technologies. Finally, we argue that despite the economic consequences of the pandemic, the funding for mental health services, including early intervention services, should be increased in line with the need for these services during and beyond the pandemic.","Ir J Psychol Med","O'Donoghue, Brian","O'Connor, Karen","Thompson, Andrew","McGorry, Patrick","32434611"],"abstract":["In the last three decades, Early Intervention for psychosis services have been established worldwide and have resulted in superior symptomatic and functional outcomes for people affected by psychotic disorders. These improved outcomes are a result of reducing delays to treatment and the provision of specialized, holistic interventions. The covid-19 pandemic poses significant challenges to the delivery of these services, such as undetected cases or long delays to treatment. Furthermore, the covid-19 pandemic will likely increase the mental health needs of communities, including the incidence of psychotic disorders. In this perspective piece, we provide suggestions as to how early intervention for psychosis services can adapt within this environment, such as utilizing novel technologies. Finally, we argue that despite the economic consequences of the pandemic, the funding for mental health services, including early intervention services, should be increased in line with the need for these services during and beyond the pandemic."],"journal":"Ir J Psychol Med","authors":["O'Donoghue, Brian","O'Connor, Karen","Thompson, Andrew","McGorry, Patrick"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434611","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1017/ipm.2020.56","topics":["Prevention"],"weight":1,"_version_":1667521393763287041,"score":386.61353},{"pmid":32321905,"title":"Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.","text":["Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.","In late March and early April 2020, the antimalarial drug, chloroquine, has been approved as an emergency treatment for the coronavirus disease 2019 (COVID-19) in the United States and in Europe. Although infrequent, neuropsychiatric symptoms have been reported in patients who received chloroquine for the treatment of malaria or autoimmune diseases. In this study, aiming to investigate these adverse events (AEs) using a large self-reporting database, we conducted a disproportionality analysis for the detection of neuropsychiatric AE signals associated with the use of chloroquine (or hydroxychloroquine), reported to FDA Adverse Event Reporting System (FAERS) database between the fourth quarter of 2012 and the fourth quarter of 2019. We included 2,389,474 AE cases, among which 520 cases developed neuropsychiatric AE following the use of chloroquine. Adjusted reporting odds ratio (ROR) for the development of each of the neuropsychiatric AEs following the use of chloroquine was calculated using a multilevel model: exposure to chloroquine was associated with a statistically significant high reporting of amnesia, delirium, hallucinations, depression, and loss of consciousness, (lower 95% confidence interval of the adjusted ROR > 1), although the degree of increase in their ROR was limited. There was no statistically significant high reporting of any other neuropsychiatric AE, including suicide, psychosis, confusion, and agitation. Current pharmacovigilance study results did not suggest any potential link between the use of chloroquine and an increased risk of suicide, psychosis, confusion, and agitation, which would be informative during the emergency use of chloroquine for the treatment of COVID-19.","Biosci Trends","Sato, Kenichiro","Mano, Tatsuo","Iwata, Atsushi","Toda, Tatsushi","32321905"],"abstract":["In late March and early April 2020, the antimalarial drug, chloroquine, has been approved as an emergency treatment for the coronavirus disease 2019 (COVID-19) in the United States and in Europe. Although infrequent, neuropsychiatric symptoms have been reported in patients who received chloroquine for the treatment of malaria or autoimmune diseases. In this study, aiming to investigate these adverse events (AEs) using a large self-reporting database, we conducted a disproportionality analysis for the detection of neuropsychiatric AE signals associated with the use of chloroquine (or hydroxychloroquine), reported to FDA Adverse Event Reporting System (FAERS) database between the fourth quarter of 2012 and the fourth quarter of 2019. We included 2,389,474 AE cases, among which 520 cases developed neuropsychiatric AE following the use of chloroquine. Adjusted reporting odds ratio (ROR) for the development of each of the neuropsychiatric AEs following the use of chloroquine was calculated using a multilevel model: exposure to chloroquine was associated with a statistically significant high reporting of amnesia, delirium, hallucinations, depression, and loss of consciousness, (lower 95% confidence interval of the adjusted ROR > 1), although the degree of increase in their ROR was limited. There was no statistically significant high reporting of any other neuropsychiatric AE, including suicide, psychosis, confusion, and agitation. Current pharmacovigilance study results did not suggest any potential link between the use of chloroquine and an increased risk of suicide, psychosis, confusion, and agitation, which would be informative during the emergency use of chloroquine for the treatment of COVID-19."],"journal":"Biosci Trends","authors":["Sato, Kenichiro","Mano, Tatsuo","Iwata, Atsushi","Toda, Tatsushi"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321905","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.5582/bst.2020.03082","keywords":["covid-19","faers","adverse events","chloroquine","pharmacovigilance","real-world data"],"locations":["United States","amnesia"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138493916545024,"score":281.6899},{"pmid":32425275,"pmcid":"PMC7228876","title":"Unravelling potential severe psychiatric repercussions on healthcare professionals during the COVID-19 crisis.","text":["Unravelling potential severe psychiatric repercussions on healthcare professionals during the COVID-19 crisis.","The coronavirus disease 2019 (COVID-19) outbreak is putting healthcare professionals, especially those in the frontline, under extreme pressures, with a high risk of experiencing physical exhaustion, psychological disturbance, stigmatization, insomnia, depression and anxiety. We report the case of a general practitioner, without relevant medical or psychiatric history that experienced a \"brief reactive psychosis (298.8)\" under stressful circumstances derived from COVID-19. She presented with delusional ideas of catastrophe regarding the current pandemic situation, delusions of self-reference, surveillance and persecution, with high affective and behavioural involvement. Physical examination and all further additional investigations did not reveal any secondary causes. She was administered olanzapine 10 mg with a significant psychopathological improvements being discharged with indications to maintain the treatment. To our knowledge this is the first case of severe mental illness in a healthcare professional without previous psychiatric history due to COVID-19 outbreak. Around 85% of patients presenting a brief psychotic disorder will develop a potentially disabling serious psychotic illness in the long-term. This case represents the potentially serious mental health consequences on healthcare professionals throughout the COVID-19 crisis and emphasizes the need to implement urgent measures to maintain staff mental health during the current pandemic.","J Affect Disord","Anmella, G","Fico, G","Roca, A","Gomez, M","Vazquez, M","Murru, A","Pacchiarotti, I","Verdolini, N","Vieta, E","32425275"],"abstract":["The coronavirus disease 2019 (COVID-19) outbreak is putting healthcare professionals, especially those in the frontline, under extreme pressures, with a high risk of experiencing physical exhaustion, psychological disturbance, stigmatization, insomnia, depression and anxiety. We report the case of a general practitioner, without relevant medical or psychiatric history that experienced a \"brief reactive psychosis (298.8)\" under stressful circumstances derived from COVID-19. She presented with delusional ideas of catastrophe regarding the current pandemic situation, delusions of self-reference, surveillance and persecution, with high affective and behavioural involvement. Physical examination and all further additional investigations did not reveal any secondary causes. She was administered olanzapine 10 mg with a significant psychopathological improvements being discharged with indications to maintain the treatment. To our knowledge this is the first case of severe mental illness in a healthcare professional without previous psychiatric history due to COVID-19 outbreak. Around 85% of patients presenting a brief psychotic disorder will develop a potentially disabling serious psychotic illness in the long-term. This case represents the potentially serious mental health consequences on healthcare professionals throughout the COVID-19 crisis and emphasizes the need to implement urgent measures to maintain staff mental health during the current pandemic."],"journal":"J Affect Disord","authors":["Anmella, G","Fico, G","Roca, A","Gomez, M","Vazquez, M","Murru, A","Pacchiarotti, I","Verdolini, N","Vieta, E"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425275","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jad.2020.05.061","keywords":["brief psychotic disorder","brief reactive psychosis","covid-19","depression","healthcare professional","mental health"],"e_drugs":["Olanzapine"],"weight":0,"_version_":1667352728886575107,"score":252.56187},{"pmid":32298803,"pmcid":"PMC7152874","title":"Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms.","text":["Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms.","The coronavirus disease 19 (COVID-19) pandemic is a significant psychological stressor in addition to its tremendous impact on every facet of individuals' lives and organizations in virtually all social and economic sectors worldwide. Fear of illness and uncertainty about the future precipitate anxiety- and stress-related disorders, and several groups have rightfully called for the creation and dissemination of robust mental health screening and treatment programs for the general public and front-line healthcare workers. However, in addition to pandemic-associated psychological distress, the direct effects of the virus itself (several acute respiratory syndrome coronavirus; SARS-CoV-2), and the subsequent host immunologic response, on the human central nervous system (CNS) and related outcomes are unknown. We discuss currently available evidence of COVID-19 related neuropsychiatric sequelae while drawing parallels to past viral pandemic-related outcomes. Past pandemics have demonstrated that diverse types of neuropsychiatric symptoms, such as encephalopathy, mood changes, psychosis, neuromuscular dysfunction, or demyelinating processes, may accompany acute viral infection, or may follow infection by weeks, months, or longer in recovered patients. The potential mechanisms are also discussed, including viral and immunological underpinnings. Therefore, prospective neuropsychiatric monitoring of individuals exposed to SARS-CoV-2 at various points in the life course, as well as their neuroimmune status, are needed to fully understand the long-term impact of COVID-19, and to establish a framework for integrating psychoneuroimmunology into epidemiologic studies of pandemics.","Brain Behav Immun","Troyer, Emily A","Kohn, Jordan N","Hong, Suzi","32298803"],"abstract":["The coronavirus disease 19 (COVID-19) pandemic is a significant psychological stressor in addition to its tremendous impact on every facet of individuals' lives and organizations in virtually all social and economic sectors worldwide. Fear of illness and uncertainty about the future precipitate anxiety- and stress-related disorders, and several groups have rightfully called for the creation and dissemination of robust mental health screening and treatment programs for the general public and front-line healthcare workers. However, in addition to pandemic-associated psychological distress, the direct effects of the virus itself (several acute respiratory syndrome coronavirus; SARS-CoV-2), and the subsequent host immunologic response, on the human central nervous system (CNS) and related outcomes are unknown. We discuss currently available evidence of COVID-19 related neuropsychiatric sequelae while drawing parallels to past viral pandemic-related outcomes. Past pandemics have demonstrated that diverse types of neuropsychiatric symptoms, such as encephalopathy, mood changes, psychosis, neuromuscular dysfunction, or demyelinating processes, may accompany acute viral infection, or may follow infection by weeks, months, or longer in recovered patients. The potential mechanisms are also discussed, including viral and immunological underpinnings. Therefore, prospective neuropsychiatric monitoring of individuals exposed to SARS-CoV-2 at various points in the life course, as well as their neuroimmune status, are needed to fully understand the long-term impact of COVID-19, and to establish a framework for integrating psychoneuroimmunology into epidemiologic studies of pandemics."],"journal":"Brain Behav Immun","authors":["Troyer, Emily A","Kohn, Jordan N","Hong, Suzi"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298803","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.bbi.2020.04.027","keywords":["covid-19","coronavirus pandemic","post-viral neuropsychiatric sequelae","public mental health"],"topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1666138493241262081,"score":240.7364}]}